Toll Free: 1-888-928-9744
Published: Jul, 2016 | Pages:
53 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Aeterna Zentaris Inc. - Product Pipeline Review - 2016 Summary Global Markets Direct's, 'Aeterna Zentaris Inc. - Product Pipeline Review - 2016', provides an overview of the Aeterna Zentaris Inc.'s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Aeterna Zentaris Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the pipeline therapeutic landscape of Aeterna Zentaris Inc. - The report provides overview of Aeterna Zentaris Inc. including its business description, key facts, and locations and subsidiaries - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report assesses Aeterna Zentaris Inc.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report features Aeterna Zentaris Inc.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects Reasons To Buy - Evaluate Aeterna Zentaris Inc.'s strategic position with total access to detailed information on its product pipeline - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Aeterna Zentaris Inc. - Identify potential new clients or partners in the target demographic - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Aeterna Zentaris Inc.'s pipeline depth and focus of pipeline therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Aeterna Zentaris Inc. Snapshot 6 Aeterna Zentaris Inc. Overview 6 Key Information 6 Key Facts 6 Aeterna Zentaris Inc. - Research and Development Overview 7 Key Therapeutic Areas 7 Aeterna Zentaris Inc. - Pipeline Review 10 Pipeline Products by Stage of Development 10 Pipeline Products - Monotherapy 11 Pipeline Products - Out-Licensed Products 12 Out-Licensed Products/Combination Treatment Modalities 13 Aeterna Zentaris Inc. - Pipeline Products Glance 14 Aeterna Zentaris Inc. - Late Stage Pipeline Products 14 Phase III Products/Combination Treatment Modalities 14 Aeterna Zentaris Inc. - Clinical Stage Pipeline Products 15 Phase II Products/Combination Treatment Modalities 15 Aeterna Zentaris Inc. - Early Stage Pipeline Products 16 IND/CTA Filed Products/Combination Treatment Modalities 16 Preclinical Products/Combination Treatment Modalities 17 Discovery Products/Combination Treatment Modalities 18 Aeterna Zentaris Inc. - Drug Profiles 19 zoptarelin doxorubicin 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 macimorelin acetate 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 ozarelix 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 AEZS-120 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 AEZS-124 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 AEZS-125 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 AEZS-126 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 AEZS-134 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 AEZS-138 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 AEZS-140 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 Small Molecules for Undisclosed Indication 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 Small Molecules to Inhibit ERK2 and Aurora B Kinase for Oncology 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 Aeterna Zentaris Inc. - Pipeline Analysis 34 Aeterna Zentaris Inc. - Pipeline Products by Target 34 Aeterna Zentaris Inc. - Pipeline Products by Route of Administration 35 Aeterna Zentaris Inc. - Pipeline Products by Molecule Type 36 Aeterna Zentaris Inc. - Pipeline Products by Mechanism of Action 37 Aeterna Zentaris Inc. - Recent Pipeline Updates 38 Aeterna Zentaris Inc. - Dormant Projects 48 Aeterna Zentaris Inc. - Discontinued Pipeline Products 49 Discontinued Pipeline Product Profiles 49 AEZS-115 49 AEZS-123 49 AEZS-131 49 AEZS-132 50 AN-215 50 AN-238 50 perifosine 50 teverelix 50 Aeterna Zentaris Inc. - Locations And Subsidiaries 51 Head Office 51 Other Locations & Subsidiaries 51 Appendix 52 Methodology 52 Coverage 52 Secondary Research 52 Primary Research 52 Expert Panel Validation 52 Contact Us 52 Disclaimer 53
List of Tables
Aeterna Zentaris Inc., Key Information 6 Aeterna Zentaris Inc., Key Facts 6 Aeterna Zentaris Inc. - Pipeline by Indication, 2016 9 Aeterna Zentaris Inc. - Pipeline by Stage of Development, 2016 10 Aeterna Zentaris Inc. - Monotherapy Products in Pipeline, 2016 11 Aeterna Zentaris Inc. - Out-Licensed Products in Pipeline, 2016 12 Aeterna Zentaris Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2016 13 Aeterna Zentaris Inc. - Phase III, 2016 14 Aeterna Zentaris Inc. - Phase II, 2016 15 Aeterna Zentaris Inc. - IND/CTA Filed, 2016 16 Aeterna Zentaris Inc. - Preclinical, 2016 17 Aeterna Zentaris Inc. - Discovery, 2016 18 Aeterna Zentaris Inc. - Pipeline by Target, 2016 34 Aeterna Zentaris Inc. - Pipeline by Route of Administration, 2016 35 Aeterna Zentaris Inc. - Pipeline by Molecule Type, 2016 36 Aeterna Zentaris Inc. - Pipeline Products by Mechanism of Action, 2016 37 Aeterna Zentaris Inc. - Recent Pipeline Updates, 2016 38 Aeterna Zentaris Inc. - Dormant Developmental Projects,2016 48 Aeterna Zentaris Inc. - Discontinued Pipeline Products, 2016 49 Aeterna Zentaris Inc., Subsidiaries 51
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.